[{"id":"e5054698-bdc5-43d3-bf35-5a0501580db7","acronym":"ASSIST_FL","url":"https://clinicaltrials.gov/study/NCT01419665","created_at":"2021-01-18T05:51:08.610Z","updated_at":"2024-07-02T16:36:30.211Z","phase":"Phase 3","brief_title":"GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)","source_id_and_acronym":"NCT01419665 - ASSIST_FL","lead_sponsor":"Sandoz","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Rixathon (rituximab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 629","initiation":"Initiation: 12/01/2011","start_date":" 12/01/2011","primary_txt":" Primary completion: 07/10/2015","primary_completion_date":" 07/10/2015","study_txt":" Completion: 01/22/2018","study_completion_date":" 01/22/2018","last_update_posted":"2021-05-14"},{"id":"61224ea8-197d-4059-86be-b496d3c429c5","acronym":"ASSIST_FL","url":"https://clinicaltrials.gov/study/NCT03814785","created_at":"2021-01-18T18:50:56.602Z","updated_at":"2024-07-02T16:37:03.506Z","phase":"Phase 3","brief_title":"GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)","source_id_and_acronym":"NCT03814785 - ASSIST_FL","lead_sponsor":"Sandoz","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Rixathon (rituximab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 629","initiation":"Initiation: 12/01/2011","start_date":" 12/01/2011","primary_txt":" Primary completion: 07/10/2015","primary_completion_date":" 07/10/2015","study_txt":" Completion: 01/22/2018","study_completion_date":" 01/22/2018","last_update_posted":"2019-01-24"},{"id":"b5c3553f-fba7-432f-b39c-23725f3d65d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01933516","created_at":"2021-01-18T08:44:31.124Z","updated_at":"2024-07-02T16:37:08.609Z","phase":"Phase 1","brief_title":"GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT01933516","lead_sponsor":"Sandoz","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive • CD20 positive + TMB-L","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • CD20 positive + TMB-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rixathon (rituximab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 08/01/2014","primary_completion_date":" 08/01/2014","study_txt":" Completion: 08/01/2014","study_completion_date":" 08/01/2014","last_update_posted":"2018-07-26"}]